• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.

作者信息

Eastham James A, Boorjian Stephen A, Kirkby Erin

机构信息

Memorial Sloan Kettering Cancer Center, New York, New York.

Mayo Clinic, Rochester, Minnesota.

出版信息

J Urol. 2022 Sep;208(3):505-507. doi: 10.1097/JU.0000000000002854. Epub 2022 Jul 5.

DOI:10.1097/JU.0000000000002854
PMID:35830561
Abstract
摘要

相似文献

1
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.临床局限性前列腺癌：美国泌尿外科学会/美国放射肿瘤学会指南
J Urol. 2022 Sep;208(3):505-507. doi: 10.1097/JU.0000000000002854. Epub 2022 Jul 5.
2
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.临床局限性前列腺癌：AUA/ASTRO/SUO 指南。第二部分：推荐方法和特定治疗方案的详细信息。
J Urol. 2018 Apr;199(4):990-997. doi: 10.1016/j.juro.2018.01.002. Epub 2018 Jan 10.
3
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.临床局限性前列腺癌：AUA/ASTRO/SUO 指南。第 I 部分：风险分层、共同决策和治疗选择。
J Urol. 2018 Mar;199(3):683-690. doi: 10.1016/j.juro.2017.11.095. Epub 2017 Dec 15.
4
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management.临床局限性前列腺癌：AUA/ASTRO 指南，第 I 部分：介绍、风险评估、分期和基于风险的管理。
J Urol. 2022 Jul;208(1):10-18. doi: 10.1097/JU.0000000000002757. Epub 2022 May 10.
5
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an AUA/ASTRO/SUO Guideline Summary.临床局限性前列腺癌：美国临床肿瘤学会（ASCO）对美国泌尿外科学会（AUA）/美国放射肿瘤学会（ASTRO）/美国泌尿外科护士协会（SUO）指南摘要的临床实践指南认可。
J Oncol Pract. 2018 Oct;14(10):618-624. doi: 10.1200/JOP.18.00434. Epub 2018 Sep 10.
6
Ethical commitment of Spanish oncologists to patients with prostate cancer: reflections on the statements of the new ASTRO/AUA guideline (2019 guideline amendment).西班牙肿瘤学家对前列腺癌患者的伦理承诺：对新的美国放射肿瘤学会/美国泌尿外科学会指南（2019年指南修订版）声明的思考
Clin Transl Oncol. 2020 Jun;22(6):802-803. doi: 10.1007/s12094-019-02200-0. Epub 2019 Aug 21.
7
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.临床局限性前列腺癌：AUA/ASTRO 指南。第三部分：放射治疗原则和未来方向。
J Urol. 2022 Jul;208(1):26-33. doi: 10.1097/JU.0000000000002759. Epub 2022 May 10.
8
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.晚期前列腺癌：AUA/ASTRO/SUO 指南 PART I.
J Urol. 2021 Jan;205(1):14-21. doi: 10.1097/JU.0000000000001375. Epub 2020 Sep 22.
9
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up.临床局限性前列腺癌：AUA/ASTRO 指南，第二部分：主动监测原则、手术原则和随访。
J Urol. 2022 Jul;208(1):19-25. doi: 10.1097/JU.0000000000002758. Epub 2022 May 10.
10
Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy.担心过度治疗：使用 AUA/ASTRO 关于根治性前列腺切除术后辅助放疗的指南。
BMC Urol. 2014 Apr 7;14:30. doi: 10.1186/1471-2490-14-30.

引用本文的文献

1
The Evolving Landscape of Novel and Old Biomarkers in Localized High-Risk Prostate Cancer: State of the Art, Clinical Utility, and Limitations Toward Precision Oncology.局限性高危前列腺癌中新旧生物标志物的演变格局：精准肿瘤学的现状、临床应用及局限性
J Pers Med. 2025 Aug 11;15(8):367. doi: 10.3390/jpm15080367.
2
Tomotherapy With Synchrony Fiducial Tracking for Stereotactic Body Radiotherapy in Prostate Cancer: A Single-Center Experience on Toxicity.采用同步基准跟踪的螺旋断层放射治疗用于前列腺癌立体定向体部放射治疗：单中心毒性经验
Cureus. 2025 May 30;17(5):e85083. doi: 10.7759/cureus.85083. eCollection 2025 May.
3
The Older the Patients, the More Aggressive the Prostate Cancer Detected Even Among Those With a Prostate-Specific Antigen Level Below the Low-Risk Threshold: Analysis Using Nationwide Korean Data.
患者年龄越大，即便前列腺特异性抗原水平低于低风险阈值，所检测出的前列腺癌侵袭性越强：基于韩国全国数据的分析
J Korean Med Sci. 2025 Apr 21;40(15):e57. doi: 10.3346/jkms.2025.40.e57.
4
Preoperative immune-inflammation index in predicting the diagnosis and adverse pathological features of prostate cancer.术前免疫炎症指数在预测前列腺癌的诊断及不良病理特征中的作用
Front Oncol. 2025 Apr 3;15:1537542. doi: 10.3389/fonc.2025.1537542. eCollection 2025.
5
External validation of inter-reader reliability of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system following focal cryoablation and focal high-intensity focused ultrasound.聚焦冷冻消融和聚焦高强度聚焦超声后前列腺局灶消融成像（PI-FAB）评分系统阅片者间可靠性的外部验证
Eur Radiol. 2025 Apr 2. doi: 10.1007/s00330-025-11513-4.
6
Clinical utility of transperineal template-guided mapping prostate biopsy in a selection of patients under active surveillance and confirmation of patients with negative biopsy for prostate cancer.经会阴模板引导靶向前列腺穿刺活检在部分接受主动监测的患者中的临床应用及前列腺癌穿刺活检阴性患者的确认
Front Oncol. 2025 Mar 14;14:1403237. doi: 10.3389/fonc.2024.1403237. eCollection 2024.
7
New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review.领域新贵：磁共振成像引导经直肠聚焦超声、经尿道前列腺汽化剜除术、局灶性激光消融、组织粉碎术——全面综述
Prostate Cancer Prostatic Dis. 2025 Mar 27. doi: 10.1038/s41391-025-00956-x.
8
Comparison of the Survivals and Adverse Events for Localized High-Risk Prostate Cancer Treated with Intensity-Modulated Radiotherapy Plus Androgen Deprivation and Trimodality Therapy, Including Low-Dose Iodine-125 Brachytherapy and External Beam Radiotherapy Plus Androgen Deprivation.调强放疗联合雄激素剥夺治疗与三联疗法（包括低剂量碘-125近距离放疗及外照射放疗联合雄激素剥夺）治疗局限性高危前列腺癌的生存率及不良事件比较
Yonago Acta Med. 2025 Jan 6;68(1):12-21. doi: 10.33160/yam.2025.02.002. eCollection 2025 Feb.
9
Ultrasound super-resolution imaging for non-invasive assessment of microvessel in prostate lesion.超声超分辨率成像用于前列腺病变微血管的无创评估。
Cancer Imaging. 2025 Jan 7;25(1):1. doi: 10.1186/s40644-024-00819-z.
10
Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment.PSMA-PET在前列腺癌诊断、分期及治疗中的当前临床应用
Cancers (Basel). 2024 Dec 21;16(24):4263. doi: 10.3390/cancers16244263.